Watching for data!
$Elevation Oncology (ELEV.US)$ Data expected readout of EO-3021 data in the latter half of 2024, which could showcase the efficacy and safety of the anti-Claudin 18.2 antibody-drug conjugate in treating advanced cancers.
Furthermore, preclinical data has shown that Elevation Oncology’s HER3-ADC candidate demonstrates significant antitumor activity, suggesting a strong foundation for future clinical evaluations
Furthermore, preclinical data has shown that Elevation Oncology’s HER3-ADC candidate demonstrates significant antitumor activity, suggesting a strong foundation for future clinical evaluations
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
